Exploratory Analysis of Autologous Stem Cell Transplantation In Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib, Lenalidomide, Dexamethasone: A Small-Scale Real-World Cohort Study in Viet Nam
Keywords:
Autologous stem cell multiple myeloma, transplantation, VietnamAbstract
Aims: To assess whether the benefits of autologous stem cell transplantation continue to be maintained in practice when combined with bortezomib, lenalidomide, and dexamethasone in the treatment of newly diagnosed multiple myeloma patients.
Methods: A retrospective cohort study of 48 patients who were new diagnosed with multiple myeloma, treated with regimen bortezomib, lenalidomide, dexamethasone (borte, lena, dexam) at Blood Transfusion and Hematology hospital, in which 23 patients were treated in combination with autologous stem cell transplantation.
Results: The study found that the VGPR rate in the autologous group was higher than in the non-autologous group, but this difference was not statistically significant. The median PFS time was not reached at the end of the study, with a median follow-up of 36 months. The 2-year PFS probability was 78.3% for the group with and without autologous stem cell transplantation, and 58.7% for the group with and without transplantation. The median OS time was 91.7% for the transplantation group and 88.8% for the non-transplantation group. The group with autologous stem cell transplantation had a significantly higher rate of complications than the group without transplantation. No deaths occurred in either group, including those over 65 years old.
Conclusion: The combination treatment of bortezomib, lenalidomide, and dexamethasone is effective and safe for newly diagnosed multiple myeloma patients, including those without transplantation and those eligible for autologous stem cell transplantation. Early stem cell collection is recommended for patients with combined treatment with autologous transplantation.
Downloads
Metrics
References
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet. Oncology. Aug 2016;17(8):e328-e346. doi:10.1016/s1470-2045(16)30206-6
Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. May 2014;28(5):1122-8. doi:10.1038/leu.2013.313
Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. Jul 1 2017;28(suppl_4):iv52-iv61. doi:10.1093/annonc/mdx096
Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. Feb 2014;28(2):258-68. doi:10.1038/leu.2013.220
Richardson PG, Jacobus SJ, Weller EA, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. The New England journal of medicine. Jul 14 2022;387(2):132-147. doi:10.1056/NEJMoa2204925
Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. British journal of haematology. Sep 2001;114(3):600-7. doi:10.1046/j.1365-2141.2001.02976.x
Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood cancer journal. Apr 8 2019;9(4):44. doi:10.1038/s41408-019-0205-9
Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. Aug 27 2009;114(9):1729-35. doi:10.1182/blood-2009-04-205013
.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
